^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Comparing survival and subsequent treatment of first-line tyrosine kinase inhibitors in patients of advanced lung adenocarcinoma with epidermal growth factor receptor mutation
Published date:
03/09/2021
Excerpt:
In this real-world data analysis with a nationwide retrospective cohort design, adult patients with newly diagnosed advanced lung adenocarcinoma with EGFR mutation...The median (95% confidence interval [CI]) OS were 24.2 (22.9-26.2), 25.7 (24.0-27.9), and 29.1 (25.8-32.1) months for those receiving gefitinib, erlotinib, and afatinib, respectively (p = 0.001).
DOI:
10.1016/j.jfma.2021.02.012
Title:
Afatinib (Giotrif) is accepted for use within NHS Scotland
Excerpt:
Afatinib (Giotrif) is accepted for use within NHS Scotland...as monotherapy, for the treatment of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).
Source:
Title:
Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Excerpt:
...Documented EGFR mutation (L858R and/or Deletion 19) with...
Trial ID:
Source:
Title:
BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
Excerpt:
...EGFR(Epidermal Growth Factor Receptor) mutation detected by central laboratory analysis of tumor biopsy material 3....
Trial ID:
More C2 evidence
Source:
Title:
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Excerpt:
...- Epidermal Growth Factor Receptor mutation detected by central laboratory analysis of tumour biopsy material....
Trial ID:
Source:
Title:
Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients
Excerpt:
...Confirmed activating EGFR mutation (exons 18-21; e.g....
Trial ID:
Source:
Title:
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Excerpt:
...Documented activating epidermal growth factor receptor mutation (Del19 and/or L858R) with tumour tissues....
Trial ID:
Source:
Title:
BI 1361849 (CV9202) + afatinib compared with placebo + afatinib in first-line NSCLC harbouring common EGFR mutations BI 1361849 (CV9202) + afatinib comparado con placebo + afatinib como tratamiento de primera línea en pacientes con NSCLC portadores de mutaciones comunes del EGFR.
Excerpt:
...Documented activating EGFR mutation (Del 19 and/or L858R) determined in tumour tissues ? ...
Trial ID:
Source:
Title:
ADAM-Afatinib Diarrhea Assessment and Management
Excerpt:
...Pathologically confirmed diagnosis of Stage IIIB or Stage IV adenocarcinoma of the lung, with EGFR mutations-positive status, who are...
Source:
Title:
Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma
Excerpt:
...- Lung adenocarcinoma patient with EGFR sensitive mutation as confirmed by needle biopsy;...
Trial ID:
Source:
Title:
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
Excerpt:
...For this study, predictive efficacy analyses will be performed with such biomarkers as EGFR mutation status. ...
Trial ID:
Source:
Title:
Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma
Excerpt:
...- Patients with Epidermal Growth Factor Receptor (EGFR) mutation-positive advanced Non-Small Cell Lung Cancer (NSCLC)...
Trial ID:
Source:
Title:
Observational Study of Afatinib 30 mg Daily
Excerpt:
...Documented EGFR mutation(s)-positive NSCLC (common mutations: Del19 and L858R) from tumour biopsy material....
Trial ID:
Less C2 evidence
Source:
Title:
Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA–IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study
Published date:
03/11/2022
Excerpt:
...patients with stage II–III EGFR-mutated adenocarcinoma who underwent cancer resection surgery at a single center were enrolled....The initial EGFR TKIs were mostly gefitinib (n = 25, 83%), and others were erlotinib (n = 3, 10%) and afatinib (n = 2, 6%). The mean disease-free survival (DFS) was 53.3 months. The 2- and 5-year DFS rate was 90.0 and 73.3%, respectively….To our knowledge, this study provides the longest experience of TKI in patients with resected EGFR mutations...
DOI:
https://doi.org/10.3389/fsurg.2022.816018
Source:
Title:
Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
Published date:
01/11/2021
Excerpt:
Afatinib was significantly associated with a longer PFS, presenting constant effectiveness in all EGFR mutation types.
DOI:
10.1186/s12885-020-07765-6
